Company Financials
Schering-Plough Exercises Rights to Centocor's CNTO 148 Anti-TNF ...
Schering-Plough Corporation has announced that it has exercised its rights to develop and commercialize with Centocor Inc., CNTO 148, a fully human ...
http://www.pharmpro.com/ShowPR~PUBCODE~021~ACCT~0000100~ISSUE~0509~RELTYPE~PR~ORIGRE...
Schering-Plough Corporation has announced that it has exercised its rights to develop and commercialize with Centocor Inc., CNTO 148, a fully human ...
http://www.pharmpro.com/ShowPR~PUBCODE~021~ACCT~0000100~ISSUE~0509~RELTYPE~PR~ORIGRE...
Musculoskeletal Report: Centocor Releases Phase II Data on CNTO ...
Centocor, Inc (HORSHAM, Pennsylvania), a wholly owned subsidiary of Johnson & Johnson, announced that phase II data showed that patients with ...
http://www.mskreport.com/articles.cfm?articleID=1168
Centocor, Inc (HORSHAM, Pennsylvania), a wholly owned subsidiary of Johnson & Johnson, announced that phase II data showed that patients with ...
http://www.mskreport.com/articles.cfm?articleID=1168
A Study of the Safety and Efficacy of CNTO 328 in Patients With ...
Further study details as provided by Centocor, Inc.: Primary Outcome Measures: ... Responsible Party: Centocor Inc. ( Director Clinical Research ) ...
http://clinicaltrials.gov/ct2/show/NCT00385827
Further study details as provided by Centocor, Inc.: Primary Outcome Measures: ... Responsible Party: Centocor Inc. ( Director Clinical Research ) ...
http://clinicaltrials.gov/ct2/show/NCT00385827
Johnson & Johnson - Investor Relations - Promising Phase 3 Data ...
In December 2007, Centocor Inc. announced that a Biologics License Application ... Centocor discovered ustekinumab and has exclusive marketing rights to the ...
http://www.investor.jnj.com/textonly/releasedetail.cfm?ReleaseID=296807
In December 2007, Centocor Inc. announced that a Biologics License Application ... Centocor discovered ustekinumab and has exclusive marketing rights to the ...
http://www.investor.jnj.com/textonly/releasedetail.cfm?ReleaseID=296807
Related Business Topics
